LRRK2 and Parkinson disease: Thus, the fact that these mutations result in hyperactivation of the LRRK2 kinase has broadened disease-modifying treatment's horizon and, indeed, LRRK2 kinase inhibitors are being developed and tested, suggesting that subjects with LRRK2 mutations may be one of the first precision medicine cohorts for PD.